5 Value Stocks In The Healthcare Sector
What are Value Stocks?
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.
The following stocks are considered to be notable value stocks in the healthcare sector:
Cronos Group (NASDAQ: CRON) - P/E: 2.52
Innoviva (NASDAQ: INVA) - P/E: 5.54
Tonix Pharmaceuticals (NASDAQ: TNXP) - P/E: 0.3
Opiant Pharmaceuticals (NASDAQ: OPNT) - P/E: 3.91
Catalyst Pharmaceuticals (NASDAQ: CPRX) - P/E: 7.62
Most recently, Cronos Group reported earnings per share at -0.19, whereas in Q1 earnings per share sat at 0.2. Cronos Group does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Innoviva’s earnings per share for Q3 sits at 0.26, whereas in Q2, they were at 0.69. Innoviva does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Tonix Pharmaceuticals has reported Q2 earnings per share at -0.23, which has increased by 37.84% compared to Q1, which was -0.37. Tonix Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Opiant Pharmaceuticals saw an increase in earnings per share from -0.4 in Q1 to -0.05 now. Opiant Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Catalyst Pharmaceuticals’s earnings per share for Q2 sits at 0.09, whereas in Q1, they were at 0.1. Catalyst Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
